共 50 条
- [2] A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients With Myeloid/Lymphoid Neoplasms With Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Rearrangement CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S430 - S431
- [4] Phase 2, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Patients with Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S350 - S351